SVRA - サバラ (Savara Inc.)

SVRAのニュース

   The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes  2021/03/17 11:43:07 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16) Affimed N.V. (NASDAQ: AFMD ) BioAtla, Inc. (NASDAQ: BCAB ) Champions Oncology, Inc. (NASDAQ: CSBR ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Omnicell, Inc. (NASDAQ: OMCL ) Savara Inc. (NASDAQ: SVRA ) (reacted to a positive analyst action and insider buying) Sierra Oncology, Inc. (NASDAQ: SRRA ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 16) Galecto, Inc. (NASDAQ: GLTO ) Immunocore Holdings plc (NASDAQ: IMCR ) Stocks In Focus Pfizer to Sell Chinese Biologics Unit to WuXi Pfizer Inc.'s (NYSE: PFE ) China unit and Hong Kong-listed WuXi Biologics announced an equity agreement under which the latter will acquire the former's state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.
   Savara Stock Rallies: Technical Analysis Levels  2021/03/16 17:54:16 Benzinga
Savara Inc. (NASDAQ: SVRA ) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target. The Short-Term Savara Chart: The 5-minute chart above shows the stock rallied following the market open and has since made a correction. Key short-term indicators to watch are the volume-weighted average price (pink) and the 200-day moving average (blue). The stock trading above the 200-day moving average brings a bullish sentiment to the stock. The stock being below the VWAP shows it can move back near the indicator before it may hold as … Full story available on Benzinga.com
   ¿Piensas comprar AstraZeneca, Apple, McDonald’s, Savara o Jabil?  2021/03/16 17:06:30 Investing.com Spain
https://es.investing.com/news/stock-market-news/piensas-comprar-astrazeneca-apple-mcdonalds-savara-o-jabil-2093986
   Pensi di comprare AstraZeneca, Apple, McDonald’s, Savara o Jabil?  2021/03/16 16:35:25 Investing.com Italy
https://it.investing.com/news/stock-market-news/pensi-di-comprare-astrazeneca-apple-mcdonalds-savara-o-jabil-1988488
   Thinking about buying stock in Can Fite, Zomedica, AMC Entertainment, Savara, or SunLink Health?  2021/03/16 14:22:00 PR Newswire
NEW YORK, March 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, ZOM, AMC, SVRA, and SSY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Savara Provides Pipeline and Business Update  2020/12/10 13:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. “I am grateful for the opportunity to be a part of the Savara team,” said Matt Pauls, Chairman and CEO, Savara. “Over the last few months, we have moved decisively and with urge
   Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences  2020/11/24 21:15:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences: Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara’s website at
   Savara (NASDAQ:SVRA) & ZIOPHARM Oncology (NASDAQ:ZIOP) Critical Review  2020/11/19 19:27:40 Transcript Daily
Savara (NASDAQ:SVRA) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations. Profitability This table compares Savara and ZIOPHARM Oncology’s net margins, return on equity and return on […]
   Savara to Present at the Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes
   Savara Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/05 21:20:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it’s clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can
   Savara Provides Pipeline and Business Update  2020/12/10 13:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. “I am grateful for the opportunity to be a part of the Savara team,” said Matt Pauls, Chairman and CEO, Savara. “Over the last few months, we have moved decisively and with urge
   Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences  2020/11/24 21:15:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences: Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara’s website at
   Savara (NASDAQ:SVRA) & ZIOPHARM Oncology (NASDAQ:ZIOP) Critical Review  2020/11/19 19:27:40 Transcript Daily
Savara (NASDAQ:SVRA) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations. Profitability This table compares Savara and ZIOPHARM Oncology’s net margins, return on equity and return on […]
   Savara to Present at the Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes
   Savara Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/05 21:20:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it’s clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can

calendar